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Abstract 
 
Ca2+ entry via Orai1 store-operated Ca2+ channels in the plasma membrane is critical to cell 
function, and Orai1 loss causes severe immunodeficiency and developmental defects.  The 
tetraspanins are a superfamily of transmembrane proteins that interact with specific ‘partner 
proteins’ and regulate their trafficking and clustering.  The aim of this study was to 
functionally characterize tetraspanin Tspan18.  We show that Tspan18 is expressed by 
endothelial cells at several-fold higher levels than most other cell types analyzed.  Tspan18-
knockdown primary human umbilical vein endothelial cells have 55-70% decreased Ca2+ 
mobilization upon stimulation with the inflammatory mediators thrombin or histamine, 
similar to Orai1-knockdown.  Tspan18 interacts with Orai1, and Orai1 cell surface 
localization is reduced by 70% in Tspan18-knockdown endothelial cells.  Tspan18 over-
expression in lymphocyte model cell lines induces 20-fold activation of Ca2+-responsive 
NFAT signaling, in an Orai1-dependent manner.  Tspan18-knockout mice are viable.  They 
lose on average 6-fold more blood in a tail-bleed assay.  This is due to Tspan18 deficiency in 
non-hematopoietic cells, as assessed using chimeric mice.  Tspan18-knockout mice have 60% 
reduced thrombus size in a deep vein thrombosis model, and 50% reduced platelet deposition 
in the microcirculation following myocardial ischemia-reperfusion injury.  Histamine- or 
thrombin-induced von Willebrand factor release from endothelial cells is reduced by 90% 
following Tspan18-knockdown, and histamine-induced increase of plasma von Willebrand 
factor is reduced by 45% in Tspan18-knockout mice.  These findings identify Tspan18 as a 
novel regulator of endothelial cell Orai1/Ca2+ signaling and von Willebrand factor release in 
response to inflammatory stimuli. 
  
 4
Introduction 
 
The tetraspanins are a superfamily of proteins containing four transmembrane regions 
that interact with and regulate the trafficking, lateral mobility and clustering of specific 
‘partner proteins’.  These include signaling receptors, adhesion molecules and 
metalloproteinases1-3.  Recently, the first crystal structure of a tetraspanin, CD81, 
demonstrated a cone-shaped structure with a cholesterol-binding cavity within the 
transmembranes4.  Molecular dynamics simulations suggest that cholesterol removal causes a 
dramatic conformational change, whereby the main extracellular region swings upwards4.  
This raises the possibility that tetraspanins function as ‘molecular switches’ to regulate 
partner protein function via conformational change, and suggests that tetraspanins are viable 
future drug targets. 
Tetraspanin Tspan18 was previously studied in chick embryos, in which it stabilizes 
expression of the homophilic adhesion molecule cadherin 6B to maintain adherens junctions 
between premigratory epithelial cranial neural crest cells5,6.  Transcriptional Tspan18 
downregulation is required for loss of cadherin 6B expression, breakdown of epithelial 
junctions and neural crest cell migration.  However, Tspan18 knockdown has no major effect 
on chick embryonic development5,6.  The function of Tspan18 in humans or mice remains 
unstudied. 
Store-operated Ca2+ entry (SOCE) through the plasma membrane Ca2+ channel Orai1 
is essential for the healthy function of most cell types7.  Loss of SOCE results in severe 
immunodeficiency that requires a bone marrow transplant for survival.  Further symptoms 
include ectodermal dysplasia and impaired development of skeletal muscle7.  The process of 
SOCE is biphasic.  This first step is initiated following the generation of the second 
messenger inositol trisphosphate (IP3) from upstream tyrosine kinase or G protein-coupled 
receptor signaling.  IP3 induces the transient release of Ca2+ from endoplasmic reticulum 
(ER) stores via IP3 receptor channels8.  Depletion of Ca2+ is detected by the ER-resident 
dimeric Ca2+-sensor protein STIM1, which then undergoes a conformational change and 
interacts with Orai1 hexamers in the plasma membrane9,10.  STIM1 binding induces Orai1 
channel opening and clustering via a mechanism that is not fully understood, allowing Ca2+ 
entry across the plasma membrane9,10.  The resulting increase in intracellular Ca2+ 
concentration is relatively large and sustained, sufficient to activate a variety of signalling 
proteins including the widely-expressed nuclear factor of activated T cells (NFAT) 
transcription factors8. 
Endothelial cells line all blood and lymphatic vessels and play a central role in 
hemostasis and in thrombo-inflammation, in which inflammatory cells contribute to 
thrombosis11,12.  In the thrombo-inflammatory disease deep vein thrombosis, blood flow 
stagnation induced by prolonged immobility, for example, is the trigger for endothelial cells 
to exocytose Weibel-Palade storage bodies via a mechanism involving Ca2+ signaling13,14.  
This releases the multimeric glycoprotein von Willebrand factor (VWF) and the adhesion 
molecule P-selectin, which recruit platelets and leukocytes, respectively.  VWF-bound 
platelets provide a pro-coagulant surface for activation of clotting factors and thrombin 
generation, neutrophils release neutrophil extracellular traps, and mast cells release 
endothelial-activating substances15-17.  This series of thrombo-inflammatory events leads to 
formation of a blood clot which occludes the vein, and can cause death by pulmonary 
thromboembolism. 
The aim of this study was to determine the function of tetraspanin Tspan18 in humans 
and mice.  We found that Tspan18 is highly expressed by endothelial cells, interacts with 
Orai1 and is required for its cell surface expression and SOCE function.  As a consequence, 
Tspan18-deficient endothelial cells have impaired Ca2+ mobilization and release of VWF 
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upon activation induced by inflammatory mediators, and Tspan18-knockout mice are 
protected from deep vein thrombosis and myocardial ischemia-reperfusion injury, and have 
defective hemostasis.  
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Methods 
 
Ethics statement 
Procedures in Birmingham were approved by the UK Home Office according to the 
Animals (Scientific Procedures) Act 1986, and those in Würzburg by the district government 
of Lower Frankonia (Bezirksregierung Unterfranken). 
 
Mice 
Tspan18-/- mice were generated by Genentech/Lexicon Pharmaceuticals on a mixed 
genetic background of 129/SvEvBrd and C57BL/6J18.  They were purchased from the Mutant 
Mouse Regional Resource Centre and bred as heterozygotes to generate litter-matched 
Tspan18-/- and Tspan18+/+ pairs.  Radiation fetal liver chimeric mice were generated as 
described19. 
 
Antibodies 
Anti-epitope tag antibodies were mouse anti-Myc 9B11 and rabbit anti-Myc 71D10 
(Cell Signaling Technology), mouse anti-FLAG M2 and rabbit anti-FLAG (Sigma).  Other 
antibodies were mouse anti-human calnexin AF18 (Abcam), rat anti-mouse CD16/32 
(BioLegend), CD41 (eBioscience) and panendothelial cell antigen MECA-32 (BD 
Pharmingen), mouse anti-ERK1/2 and rabbit anti-phospho-ERK1/2 (Cell Signaling 
Technology) and rabbit anti-human VWF (GE Healthcare).  Biotinylated isolectin GS-IB4 
glycoprotein was from ThermoFisher Scientific. 
 
Expression constructs 
The NFAT/AP1-luciferase transcriptional reporter construct was described 
previously20,21.  pEF6/Myc-His (mock) and pEF6/Myc-His/lacZ were from Invitrogen.  N-
terminal FLAG-tagged tetraspanin constructs were generated in pEF6/Myc-His as 
described22,23.  pcDNA3.1 Myc-His-tagged human Orai1 and MO70-FLAG-tagged human 
Orai1 E106Q were from Addgene24 and the dominant-active calcineurin was as described25. 
 
Cell culture and transfections 
Detailed information on cell cultures is provided in the Online Supplemental 
Material.  Wild-type and IP3 receptor-deficient DT40 chicken B-cell lines26, and Jurkat 
human T-cell line, were transfected by electroporation21.  Human embryonic kidney (HEK)-
293T (HEK-293 cells expressing the large T-antigen of simian virus 40) and the human HeLa 
epithelial cell line were transfected using polyethylenimine (Sigma)27 and Lipofectamine 
2000 (Invitrogen)28, respectively.  Human umbilical vein endothelial cells (HUVECs)29 were 
transfected with 10 nM Silencer Select siRNA duplexes (Invitrogen) using Lipofectamine 
RNAiMAX (Invitrogen). 
 
Quantitative real-time polymerase chain reaction (PCR) 
Quantitative real-time PCR was performed using TaqMan assays for Tspan18, Orai1, 
Orai2, Orai3, 18S and GAPDH30.  Detailed information is in Online Supplemental Material. 
 
Lentiviral transduction 
HUVECs were lentivirally transduced with Orai1-Myc as described31.  Detailed 
information is in Online Supplemental Material. 
 
NFAT/AP-1-luciferase transcriptional reporter assay 
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The NFAT/AP-1-luciferase assay, and β-galactosidase assay to normalize for 
transfection efficiency, were as described21. 
 
Co-immunoprecipitation 
A detailed description of co-immunoprecipitation from transfected HEK-293T cell 
lysates22 is provided in Online Supplemental Material. 
 
Immunofluorescence microscopy 
Detailed information is in Online Supplemental Material.  In brief, cells were 
prepared as described29 and the Manders coefficients (M1 and M2) were used as the 
colocalization measure32.  Ear vasculature was imaged and quantified as described33,34. 
 
Immunohistochemistry 
 Immunohistochemistry was as described35; detailed information is in Online 
Supplemental Material. 
 
Intracellular Ca2+ 
HUVECs were loaded with Fluo-4 NW dye according to the manufacturer’s 
instructions (Molecular Probes).  Fluorescence was measured every 3 seconds for 5 minutes 
using a FlexStation fluorescence reader (Molecular Devices), and thrombin (1 U/ml), 
histamine (20 µM) or ionomycin (10 µM) were injected after acquiring a baseline for 30 
seconds. 
 
ELISA and coagulation time assays 
Detailed information is in Online Supplemental Material. 
 
Platelet aggregation and adhesion to HUVECs 
Platelet assays were as described36,37; detailed information is in Online Supplemental 
Material. 
 
In vivo assays 
Mouse models were as described13,37-39; detailed information is in Online 
Supplemental Material. 
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Results 
 
Tspan18 is expressed by endothelial cells 
A lack of effective antibodies to many tetraspanins is a current problem in the 
tetraspanin field.  This may be due to their relatively small size, high degree of sequence 
conservation during evolution and compact four-transmembrane structure4.  For example, no 
Tspan18 antibodies have been published, and commercially-available antibodies are made to 
Tspan18 peptides and do not detect full-length Tspan18 when rigorously tested (Tomlinson 
M.G., unpublished).  Therefore, to characterize the Tspan18 expression profile, mouse tissues 
were tested by quantitative real-time PCR.  Tspan18 mRNA was most highly expressed in 
lung and at lower levels in other tissues (Figure 1A).  Analyses of published transcriptomic 
data40 showed that Tspan18 was most highly expressed by endothelial cells compared to 
other mouse lung cell types (Figure 1B).  Similar analyses of transcriptomic data from mouse 
brain41 also showed relatively strong endothelial expression of Tspan18 (Figure 1C).  
Consistent with this, quantitative real-time PCR showed that Tspan18 was expressed by 
primary human umbilical vein endothelial cells (HUVECs) and the human microvascular 
endothelial HMEC-1 cell line (Figure 1D).  Tspan18 expression was low or absent on most 
other cell types tested, although peripheral blood leukocytes expressed comparable levels to 
HUVECs (Figure 1D).  In transcriptomic data from the Human Protein Atlas 
(www.proteinatlas.org), Tspan18 was expressed by most human tissues at a level between 10 
and 70 tags per million, but in cell lines was only expressed at 10 or greater tags per million 
by HUVECs and 8 of the other 64 cell types analyzed42. 
 
Tspan18 is required for Ca2+ signalling in primary human endothelial cells 
To investigate Tspan18 function, its expression in HUVECs, which are a widely-used 
primary human endothelial cell model, was knocked down using two different siRNA 
duplexes.  Subsequent analyses revealed a 60% reduction in peak Ca2+ elevation in response 
to the inflammatory mediator thrombin (Figure 2A).  A similar defect was observed in 
response to histamine (Figure 2B).  Positive control ionomycin treatment gave a sustained 
intracellular Ca2+ response in all samples (Figure 2C) and effective knockdown was 
confirmed by quantitative real-time PCR (Figure 2D).  Functionality of thrombin and 
histamine receptors was confirmed by anti-phospho-ERK1/2 mitogen-activated protein 
kinase (MAPK) western blotting, as this was not affected by Tspan18 knockdown (Figure 
2E). 
 
Tspan18 promotes Ca2+-responsive NFAT signalling in lymphocyte cell lines 
To investigate the mechanism by which Tspan18 regulates Ca2+ signalling, a more 
tractable cell line system was established, namely DT40 cells that are derived from chicken 
B-cells.  In this cell line, a transfected nuclear factor of activated T cells (NFAT)/adapter 
protein 1 (AP-1) transcriptional luciferase reporter can be used as a readout for Ca2+ 
signalling downstream of transfected membrane proteins21,43.  Transfection of a FLAG 
epitope-tagged Tspan18 expression construct was sufficient to induce robust NFAT/AP-1 
activation (Figure 3A).  As controls, five other FLAG-tagged tetraspanins (CD9, CD63, 
CD151, Tspan32 and Tspan9) were chosen because they represent a diverse range of 
tetraspanins based on sequence identities22.  These did not induce NFAT/AP-1 activation, 
despite their substantially higher expression than Tspan18 as assessed by anti-FLAG western 
blotting (Figure 3A). 
Despite the fact that the NFAT/AP-1 promoter can be activated by Ca2+ signalling, it 
is maximally activated by combined Ca2+ signalling and MAPK; Ca2+ activates NFAT and 
MAPK activates AP-1.  To determine whether Tspan18 activates Ca2+ signalling, MAPK or 
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both, Tspan18-transfected DT40 cells were stimulated with the Ca2+ ionophore ionomycin or 
phorbol ester PMA to activate the MAPK pathway.  PMA synergized with Tspan18 
expression in activating NFAT/AP-1, but ionomycin did not (Figure 3B).  As a positive 
control, combined PMA and ionomycin induced relatively strong NFAT/AP-1 activation in 
the presence or absence of Tspan18 (Figure 3B).  The capacity of Tspan18 over-expression to 
induce NFAT/AP-1 activation was not restricted to DT40 B-cells, since similar data were 
obtained in the human Jurkat T-cell line (Figure 3C).  Taken together, these data suggest that 
Tspan18 promotes Ca2+ signalling and NFAT activation via a mechanism that is common to 
endothelial cells, B-cells and T-cells. 
 
Tspan18-induced NFAT activation requires functional Orai1 SOCE channels 
To understand the mechanism by which Tspan18 promotes Ca2+ signalling, a series of 
NFAT/AP-1 reporter experiments were conducted in gene-knockout DT40 cells and using 
inhibitors and a dominant-interfering construct.  Firstly, Tspan18-induced NFAT/AP-1 
activation was found to be independent of the three IP3 receptors (Figure 3D).  IP3 receptors 
release Ca2+ from ER stores in response to tyrosine kinase and G protein-coupled receptor 
activation, suggesting that Tspan18 does not operate on these pathways or IP3 receptors 
themselves.  However, Tspan18 did not activate NFAT/AP-1 following chelation of 
extracellular Ca2+ (Figure 3E), or following treatment with the immunosuppressive drug 
cyclosporin A (Figure 3F), which prevents NFAT translocation to the nucleus by inhibiting 
its activatory phosphatase calcineurin.  These data suggest that Tspan18 might induce Ca2+ 
entry via the SOCE channel Orai1, a major entry route for extracellular Ca2+ in non-excitable 
cells8.  Consistent with this possibility, a dominant interfering form of Orai1 (E106Q), which 
multimerizes with endogenous Orai1 to yield a non-functional channel44-46, inhibited 
Tspan18-induced NFAT/AP-1 activation (Figure 3G).  As a positive control to confirm that 
downstream NFAT signalling was still intact in the presence of dominant interfering Orai1, 
its inhibitory effect was overcome by the expression of an active form of calcineurin (Figure 
3G).  Therefore, Tspan18 may activate Ca2+ entry through the Orai1 SOCE pathway. 
 
Tspan18 interacts with Orai1 
To investigate whether Tspan18 interacts with Orai1, transfected epitope-tagged 
proteins were used because of the lack of effective antibodies to Tspan18.  To test for an 
interaction using co-immunoprecipitation, transfected HEK-293T cells were lyzed in 1% 
digitonin, a stringent detergent that has been used previously to identify tetraspanin-partner 
protein interactions22,47.  FLAG-tagged Tspan18 co-immunoprecipitated with Myc-tagged 
Orai1, but five other control tetraspanins did not (Figure 4A).  Moreover, Tspan18 and Orai1 
co-localized when expressed in HeLa cells, at a level of approximately 90% pixel co-
localisation when assessed using the Manders’ Coefficient (Figure 4B).  These data suggest 
that Tspan18 interacts with Orai1. 
 
Orai1-knockdown endothelial cells have impaired Ca2+ mobilization and Orai1 surface 
expression requires Tspan18 
To determine whether knockdown of Orai1 could phenocopy Tspan18 knockdown, 
intracellular Ca2+ mobilisation was measured following siRNA-mediated knockdown of 
Orai1.  This resulted in impaired Ca2+ mobilisation in response to thrombin (Figure 5A) or 
histamine (Figure 5B).  As a control, knockdown of the other Orai family members, Orai2 
and Orai3, did not affect Ca2+ mobilisation (Figures 5A-B), in agreement with previous 
studies on Orai proteins in HUVECs48,49.  Positive control ionomycin treatment gave a 
sustained intracellular Ca2+ response in all samples (Figure 5C) and effective knockdown was 
confirmed by quantitative PCR (Figures 5D-F). 
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A common mechanism of tetraspanin function is to regulate their partner proteins by 
facilitating their exit from the endoplasmic reticulum (ER) and trafficking to the cell 
surface1,50,51.  To determine whether Orai1 localisation could be regulated by Tspan18 in this 
manner, HUVECs were lentivirally transduced with Myc-Orai1 and transfected with control 
or Tspan18 siRNA duplexes, and Orai1 subcellular localisation assessed by confocal 
microscopy.  Orai1 was localized primarily to the cell periphery in control cells, but was this 
reduced following Tspan18 knockdown, with Orai1 partially co-localized with the ER marker 
calnexin (Figure 5G).  Quantitative analyses showed that approximately 40% of Orai1 was 
ER-localized in Tspan18 knockdown cells compared to 10-15% in control cells.  This partial 
co-localization could be due to some Orai1 localization in the Golgi and/or trans-Golgi 
network, as shown by staining close to the nucleus, rather than the more extended perinuclear 
reticular staining of the ER (Figure 5G).  These data support a role for Tspan18 in regulating 
Orai1 exit from the ER, and/or Golgi, and trafficking to the cell surface. 
 
Tspan18 deficient mice have impaired hemostasis due to a defect in non-haematopoietic 
cells 
To investigate Tspan18 function in vivo, Tspan18-knockout mice were acquired from 
Genetech/Lexicon Pharmaceuticals.  These mice had been generated as part of a library of 
472 knockouts18, but were functionally uncharacterized.  Breeding of heterozygotes gave an 
equal proportion of male and female mice with Mendelian genotype ratios, and the mice bred 
successfully as homozygote knockouts (data not shown).  Furthermore, Tspan18-knockout 
mice had normal body weights and whole blood cell counts (data not shown). 
Tspan18-knockout mice were first evaluated for a hemostasis phenotype using a tail 
bleed assay.  Most Tspan18-knockout mice bled more than wild-type littermates, 
demonstrating a significant disruption to hemostasis (Figure 6A).  Some Tspan18-knockout 
mice did not bleed excessively (Figure 6A), indicating that the bleeding phenotype was 
variable.  This variability could be due to genetic modifier loci, as demonstrated in mice 
deficient for the platelet collagen/fibrin receptor GPVI52.  To determine whether impaired 
hemostasis was due to loss of Tspan18 from hematopoietic or non-hematopoietic cells, tail 
bleeding assays were performed on radiation fetal liver chimeric mice.  These demonstrated 
that the bleeding phenotype was due to Tspan18 loss from non-hematopoietic cells (Figure 
6A), and suggests that a platelet defect is not responsible.  Consistent with this, Tspan18-
knockout platelets aggregated normally in response to collagen (Figure 6B) or thrombin 
(Figure 6C).  Furthermore, prothrombin time and activated partial thromboplastin time tests 
showed that coagulation was similar for wild-type and Tspan18-knockout plasma (Figures 
6D-E).  These data suggest that the impaired hemostasis phenotype is due to a defect in a 
non-hematopoietic vascular cell type such as the endothelial cell.  This did not appear to be 
due to any observable structural defects in the vasculature, because immunohistochemistry 
analyses of blood vessels in organs such as kidney and pancreas were similar for wild-type 
and Tspan18-knockout mice (Figure 6F), as were immunofluorescence analyses of blood 
vessels in the ear (Figure 6G). 
 
Tspan18 and Orai1 are required for endothelial release of VWF in response to 
inflammatory mediators 
Endothelial cell stimulation by inflammatory agonists induces VWF release from 
Weibel-Palade bodies via a process that involves Ca2+ signalling14.  To investigate whether 
Tspan18 could be required for VWF release, HUVECs were subjected to Tspan18 
knockdown and stimulated in culture medium with thrombin or histamine.  Soluble VWF 
release, as detected by ELISA, was reduced by approximately 90% compared to control cells 
(Figure 7A).  This was corroborated by immunofluorescent staining of VWF that showed 
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minimal release of Weibel-Palade bodies after Tspan18 knockdown (Figure 7B).  Similar to 
Tspan18, Orai1 knockdown reduced Weibel-Palade body release after thrombin stimulation, 
but knockdown of Orai2 or Orai3 had no effect (Figure 7C).  Furthermore, Tspan18 
knockdown reduced platelet adhesion to a thrombin-activated HUVEC monolayer by 85-90% 
(Figure 7D).  These data support a role for Tspan18 and Orai1 in VWF release and platelet 
capture following endothelial cell activation by inflammatory mediators. 
 
Tspan18-knockout mice have impaired histamine-induced release of endothelial VWF 
and impaired thombo-inflammatory responses 
To determine whether Tspan18 has a role in VWF release in vivo, Tspan18-knockout 
mice were intra-peritoneally injected with histamine, and plasma VWF levels analyzed by 
ELISA.  Induced plasma VWF release was reduced by approximately 50% in the absence of 
Tspan18 (Figure 8A).  Basal plasma VWF was normal in Tspan18-knockout mice (Figure 
8A), indicating a requirement for Tspan18 in regulated, but not basal, VWF release. 
To investigate the role of Tspan18 in thrombosis, two arterial thrombosis models and 
two thrombo-inflammatory models were used.  In a platelet-driven aorta injury arterial 
thrombosis model38, no difference in time to complete occlusion of the vessel between 
Tspan18-knockout and wild-type littermate control mice was observed (Figure 8B).  
Similarly, there was no thrombosis defect in mesenteric arterioles following application of 
FeCl3 (Figure 8C), which is also a platelet-driven model38, but shows reduced platelet 
deposition and thrombus formation in the complete absence of VWF53,54.  In a deep vein 
thrombosis thrombo-inflammatory model that is dependent on endothelial VWF13, thrombus 
length and weight were reduced by approximately 60% in the Tspan18-knockout mice, 
compared to wild-type littermate controls (Figure 8D).  Moreover, 4 out of 9 Tspan18-
knockout mice failed to develop a thrombus compared to 100% thrombus formation in wild-
type (Figure 8D).  Macroscopically, thrombi from Tspan18-knockout mice had similar red 
and white parts to those from wild-type mice (data not shown).  Finally, in a VWF-dependent 
myocardial ischemia-reperfusion thrombo-inflammatory model55,56, platelet deposition and 
aggregate size in the microcirculation were reduced by approximately 50% (Figure 8E).  The 
reduction in severity in the two thrombo-inflammatory models is consistent with the 
requirement of Tspan18 for endothelial VWF release in response to inflammatory mediators. 
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Discussion 
 
We have discovered that Tspan18 is expressed by endothelial cells and interacts with 
the SOCE channel Orai1.  Tspan18-knockdown endothelial cells had reduced Orai1 
expression at the cell surface and impaired Ca2+ signaling.  This is consistent with the 
established role of tetraspanins in interacting with specific partner proteins in the ER, and 
promoting their trafficking to the cell surface1,50,51, albeit via mechanisms that are yet to be 
defined.  Tspan18 is not particularly related to any of the other 32 mammalian tetraspanins22, 
suggesting that it may be unique amongst tetraspanins in regulating Orai1.  Indeed, none of 
the five tetraspanins that were selected as controls interacted with Orai1, or induced Ca2+-
responsive NFAT activation, when over-expressed. 
 At the cell surface, tetraspanins can regulate the lateral diffusion and clustering of 
their partner proteins2,3.  A question that arises from the present study is whether Tspan18 
regulates Orai1 clustering at the endothelial cell surface.  Interestingly, a unimolecular 
coupling model of Orai1 activation was recently proposed, whereby one molecule of a 
STIM1 dimer is sufficient to induce opening of the Orai1 hexamer channel10.  This would 
enable the other STIM1 molecule in the dimer to cross-link with a second Orai1 hexamer and 
form a lattice of clustered Orai1 channels.  The degree of cluster formation could dictate the 
kinetics of channel activation and could concentrate Ca2+ influx to particular regions of the 
plasma membrane10.  This could affect the extent to which downstream effectors are 
activated.  Tetraspanins have been reported to exist as nanodomains of approximately ten 
tetraspanins of a single type57, therefore Tspan18 may cluster Orai1 into pre-formed 
nanodomains, so modulating Orai1 lattice formation by STIM1.  This may provide a means 
by which endothelial cells fine-tune SOCE and downstream functional responses.  It remains 
to be determined whether Tspan18 also regulates Orai2 and Orai3, but we found no role for 
these Orai family members in inflammatory mediator-induced HUVEC Ca2+ mobilization, 
consistent with other studies48,49. 
 The inflammatory mediators thrombin and histamine activate G protein-coupled 
receptors to induce downstream Ca2+ mobilization and the release of VWF from Weibel-
Palade bodies14.  Consistent with impaired Ca2+ signaling, Tspan18-knockout endothelial 
cells had impaired inflammatory mediator-induced VWF release in vitro and in vivo.  In 
contrast, basal release of VWF appeared to be normal, because basal plasma VWF levels 
were unaffected in Tspan18-knockout mice.  We hypothesize that impaired VWF release, in 
response to inflammatory mediators, explains the in vivo phenotypes observed in Tspan18-
knockout mice.  The protection from deep vein thrombosis is consistent with the central role 
of VWF in this disease13.  Furthermore, the reduced platelet deposition in the 
microcirculation during myocardial ischemia-reperfusion injury is consistent with the role of 
VWF in this process55,56.  The hemostasis defect cannot be explained at present, because 
although a tail bleeding phenotype has been demonstrated in endothelial-specific VWF-
knockout mice, these animals also had low plasma VWF58,59, unlike Tspan18 knockouts.  The 
tail bleeding assay measures blood loss following excision of the tip of the tail, which 
contains the two lateral veins, the dorsal vein and the ventral artery.  We speculate that 
endothelial cells in the veins and artery, adjacent to the site of excision, are activated and 
release VWF via Ca2+-dependent signaling.  The VWF may trap platelets, facilitating their 
aggregation and preventing excessive blood loss from the site of tail injury.  Therefore, our 
data suggest that acute release of VWF adjacent to a site of injury might be important for 
hemostasis, at least for some types of injury.  Finally, the lack of a phenotype in the two 
arterial thrombosis models is consistent with the importance of platelets in these models38, 
and we found no defect in aggregation in vitro for Tspan18-knockout platelets. 
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In summary, we have identified Tspan18 as a novel regulator of endothelial Orai1 and 
SOCE.  Our in vivo data show that Tspan18 regulates inflammation-induced VWF release 
but not basal release, and promotes hemostasis and thrombo-inflammatory processes but not 
arterial thrombosis. 
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Figure Legends 
 
Figure 1.  Tspan18 is highly expressed by endothelial cells and Tspan18-knockdown 
endothelial cells have impaired Ca2+ mobilization.  (A) Quantitative real-time PCR was 
carried out for Tspan18 using cDNA derived from a panel of mouse tissues.  Data were 
normalized for the HPRT housekeeping gene and adjusted such that the lung value was 100 
in each experiment.  Error bars represent standard error of the mean from three independent 
tissue samples.  (B) RNA-Seq data from major cell types in mouse lung, generated by Du et 
al40, was used to show Tspan18 mRNA expression levels as fragments per kilobase of 
transcript sequence per million mapped fragments (FPKM).  (C) RNA-Seq data from major 
cell types in mouse brain, generated by Zhang et al41, was used to show Tspan18 mRNA 
expression levels as described in panel B.  (D) Quantitative real-time PCR was carried out for 
Tspan18 on cDNA derived from a panel of primary human cells (dermal fibroblasts, aortic 
smooth muscle, hepatocytes, peripheral blood leukocytes from buffy coat and human 
umbilical vein endothelial cells (HUVECs)), and human cell lines (HEK-293T human 
embryonic kidney cells, MDA-MB-231 epithelial cells, DAMI megakaryocytic cells, HEL 
and K562 erythroleukemia cells, U937 monocytic cells, Jurkat and HPB-ALL T cells, DG75 
and Raji B cells and HMEC-1 microvascular endothelial cells).  Data were normalized for 
actin and adjusted such that the HUVEC value was 100 in each experiment.  Error bars 
represent standard error of the mean from two independent cell samples.   
 
Figure 2.  Tspan18-knockdown endothelial cells have impaired Ca2+ mobilization.  (A-
D) Human umbilical vein endothelial cells (HUVECs) were transfected with a negative 
control siRNA (CON) or with one of two independent siRNAs targeting Tspan18 (T18 KD).  
48 hours later, HUVECs were loaded with the Ca2+-sensitive dye Fluo-4 NW and Ca2+ 
measurements taken using a FlexStation fluorescence reader during addition (arrow) of (A) 1 
U/ml thrombin, (B) 20 μM histamine, or (C) 10 µM ionomycin.  Representative Ca2+ traces 
are shown for Tspan18-knockdown HUVECs (left panels), with quantitation of maximum 
intracellular Ca2+ concentrations (right panels).  Data were analyzed by one-way ANOVA 
with Dunnett’s multiple comparisons test.  Error bars represent the standard error of the mean 
from three independent experiments (*P<0.05 and ***P<0.001).  (D) siRNA-transfected 
HUVECs from panels A-B were harvested, mRNA extracted, cDNA produced and Tspan18 
mRNA levels were assessed by quantitative real-time PCR.  Data were normalized to 18S 
and actin as internal controls and adjusted such that the non-siRNA-transfected mock value 
was 1 in each experiment.  Data were then normalized by logarithmic transformation, and 
analyzed by one-way ANOVA and Tukey’s multiple comparison test.  Error bars represent 
the standard error of the mean from three independent experiments (***P<0.001).  (E) 
HUVECs were subjected to Tspan18 siRNA knockdown as described for panels A-D, 
stimulated with 1 U/ml thrombin or 20 μM histamine for 5 minutes, then whole cell lysates 
were analyzed by western blotting with phospho-ERK1/2 and total ERK1/2 antibodies.  
Representative blots are shown in the left panel and quantitation of three independent 
experiments is shown on the right.  Error bars represent standard error of the mean.  
Knockdown efficiency was similar to that shown in panel D (data not shown). 
 
Figure 3.  Tspan18 over-expression in cell lines activates Ca2+-responsive NFAT 
signalling in an Orai1-dependant manner.  (A) The DT40 B cell line was transfected with 
an NFAT/AP-1-luciferase reporter construct, a β-galactosidase expression construct driven 
by the elongation factor (EF)-1α promoter to control for transfection efficiency, and FLAG-
tagged mouse tetraspanin constructs or empty vector control.  24 hours post-transfection, 
cells were lyzed and assayed for luciferase and β-galactosidase.  Luciferase data were 
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normalized for β-galactosidase values (left panel).  Whole cell lysates from these cells were 
separated by SDS-PAGE and blotted with an anti-FLAG antibody.  A representative blot is 
shown (right panel).  (B-C) The DT40 B cell line (B) and the human Jurkat T cell line (C) 
were transfected with an NFAT/AP-1-luciferase reporter construct and β-galactosidase 
expression construct with (+) or without (-) FLAG-tagged mouse Tspan18.  24 hours post-
transfection cells were stimulated for six hours with 50 nM PMA or 1 µM ionomycin (Iono) 
(left panels), or both together (right panels).  Luciferase assays were then performed as 
described in panel A.  (D) DT40 cells with (+) or without (-) expression of FLAG-tagged 
mouse Tspan18 were tested for NFAT/AP-1 luciferase activity as described in panel A, but 
using cells with gene knockouts of the three IP3 receptors (IP3R-) in comparison to wild-type 
(WT) cells (left panel).  Whole cell lysates were western blotted with an anti-FLAG antibody 
(right panel).  (E-F) DT40 cells with (+) or without (-) expression of FLAG-tagged mouse 
Tspan18 were tested for NFAT/AP-1 luciferase activity as described in panel A, except that 
cells were treated with 4 mM EGTA as a Ca2+ chelator (E) or with 2 mM cyclosporin A as a 
calcineurin inhibitor (F).  (G) DT40 cells were transfected with FLAG-tagged human 
Tspan18 in the presence or absence of a dominant negative human Orai1 E106Q mutant 
construct, or a consitutively active human calcineurin construct.  The experiment was 
conducted as described in panel A.  All luciferase data were corrected for β-galactosidase 
values, normalized by logarithmic transformation, and analyzed by one-way ANOVA and 
Tukey’s multiple comparison test (*P<0.05, **P<0.01 and ***P<0.001).  Error bars 
represent the standard error of the mean from at least three independent experiments. 
 
Figure 4.  Tspan18 interacts with Orai1.  (A) HEK-293T cells were tranfected with a Myc-
tagged human Orai1 expression construct and one of a panel of FLAG-tagged human 
tetraspanin constructs.  Cells were lyzed in 1% digitonin and immunoprecipitated with an 
anti-FLAG antibody.  Samples were seperated by SDS-PAGE and both immunoprecipitated 
(i.p.) and whole call lysate (wcl) samples were blotted with anti-FLAG and anti-Myc 
antibodies.  A representative blot for each is shown (left panel) with quantitation of Myc-
tagged Orai1 immunoprecipitated with the tetraspanins (right panel).  Data were nomalized 
by logarithmic transformation before analysis by one-way ANOVA and Dunnet’s post-test.  
Error bars represent standard error of the mean from three independent experiments 
(*P<0.05).  (B)  HeLa cells were transfected with Myc-tagged human Orai1, FLAG-tagged 
human Tspan18, or both constructs.  Cells were fixed and stained with an anti-Myc antibody 
(green), an anti-FLAG antibody (red) and imaged by confocal microscopy (left panels).  The 
Manders coefficients (M1 and M2) were calculated from the confocal stacks to quantify the 
degree of overlap (right panel).  Error bars represent the standard error of the mean from 
three independent experiments. 
 
Figure 5.  Orai1-knockdown endothelial cells have impaired Ca2+ mobilization and 
Orai1 surface expression requires Tspan18.  (A-F) Human umbilical vein endothelial cells 
(HUVECs) were transfected with a negative control siRNA (CON) or with one of two 
independent siRNAs targeting Orai1, Orai2 or Orai3 (Orai1-3 KD).  48 hours later, Ca2+ 
measurements were taken as described in Figure 1E-G, following addition of 1 U/ml 
thrombin (A), 20 μM histamine (B), or 10 µM ionomycin (C), and quantitation of maximum 
intracellular Ca2+ concentrations is shown.  Error bars represent standard error of the mean 
from three independent experiments (**P<0.01 and ***P<0.001).  (D-F) siRNA-transfected 
HUVECs from panels A-C were subjected to quantitative real-time PCR for Orai1 (D), Orai2 
(E) or Orai3 (F) as described for Figure 1H.   Error bars represent standard error of the mean 
from three independent experiments (***P<0.001).  (G) HUVECs lentivirally-transduced to 
express Myc-tagged Orai1 were treated with control or Tspan18 siRNAs.  Cells were stained 
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with anti-Myc (white) or anti-calnexin endoplasmic reticulum marker (red) antibodies and 
representative confocal microscopy images shown (upper panels).  In the line graphs below 
the images (lower panels), the percentage expression of Orai1 (black) and calnexin (red) 
across the yellow line in the upper panel was determined using ImageJ.  The percentage of 
Orai1 that localized to a calnexin endoplasmic reticulum mask was then quantified (right 
panel).  Data were generated from 15 cells per condition from three independent experiments 
(five cells per condition per experiment).  Error bars represent the standard error of the mean 
(***P<0.001). 
 
Figure 6.  Tspan18-knockout mice have a hemostasis defect due to the absence of 
Tspan18 expression by non-hematopoietic cells.  (A) Tail bleeding assays were done by 
amputating 3 mm tail tips of anaesthetized mice and the weight of blood lost was measured.  
The mice were Tspan18+/+, Tspan18-/-, or lethally irradiated Tspan18-/- or Tspan18+/+ mice 
reconstituted with fetal liver cells from Tspan18+/+ or Tspan18-/- embryos.  Each symbol 
represents one animal.  All data were analyzed by Fisher’s exact test (*P<0.05 and 
***P<0.001).  Note that bleeding was stopped by cauterizing the tails of some mice, because 
of regulations limiting the amount of blood loss on our Home Office License.  (B-C) Washed 
platelets from Tspan18+/+ or Tspan18-/- mice were activated with 3 µg/ml collagen (B) or 0.3 
U/ml thrombin (C), and aggregation was measured by light transmission with stirring.  
Quantitated percentage aggregation each minute is shown.  Error bars represent the standard 
error of the mean from at least three pairs of litter-matched mice.  (D-E) Plasma samples 
from Tspan18+/+ and Tspan18-/- mice were subjected to a prothrombin time test with human 
placental thromboplastin (D) and an activated partial thromboplastin time test with purified 
soy phosphatides with ellagic acid (E).  Error bars represent the standard error of the mean 
from four pairs of litter-matched mice.  (F) Immunohistochemistry was used to show a 
grossly normal vasculature in Tspan18+/+ and Tspan18-/- mice formalin-fixed paraffin-
embedded 5 μm sections from kidney and pancreas, using the MECA32 anti-mouse 
panendothelial cell antibody.  Images are representative of three pairs of litter-matched mice.  
(G) Confocal microscopy was used to show a grossly normal vasculature in Tspan18+/+ and 
Tspan18-/- mice ears, by staining anterior ear tissue with biotinylated isolectin GS-IB4 
glycoprotein followed by Alexa647-conjugated streptavidin.  Images are representative of 
three pairs of litter-matched mice.  ImageJ quantitation of 3 fields of view (500 x 500 pixels) 
per mouse showed a mean total vessel length of 11131±1271 pixels for Tspan18+/+ and 
11684±283 pixels for Tspan18-/- (n=3; error represents standard error of the mean). 
 
Figure 7.  Tspan18-knockdown endothelial cells have impaired histamine- and 
thrombin-induced release of VWF.  (A) Human umbilical vein endothelial cells (HUVECs) 
were transfected with a negative control siRNA (CON) or with one of two independent 
siRNAs targeting Tspan18 (T18 KD).  48 hours later, HUVECs were stimulated with 1 U/ml 
thrombin or 20 μM histamine for 5 minutes.  Cultured media was removed and assayed for 
VWF by ELISA.  Pre-stimulation levels of von Willebrand factor (VWF) were subtracted 
from these data.  Error bars represent the standard error of the mean from three experiments 
(**P<0.01).  (B) HUVECs transfected as described in panel A were stimulated with 1 U/ml 
thrombin for 5 minutes, and the cells were fixed and stained with an anti-VWF antibody 
followed by Alexa488-conjugated secondary antibody.  Representative confocal microscopy 
images are shown (left panels).  Z-stack images were de-noised, background-subtracted and 
analyzed for the number of VWF cellular bodies, using ImageJ.  Counts were made on five to 
ten cells per experiment for four independent experiments (right panel).  Error bars represent 
the standard error of the mean (***P<0.001 and ns denotes not significant).  (C) The 
experiment and quantitation was conducted as for panel B, except HUVECs were mock-
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transfected with no siRNA (Mock), transfected with negative control siRNA (CON), or 
siRNA to Orai1, Orai2 or Orai3 (KD).  (D) HUVECs were siRNA-transfected and simulated 
with 1 U/ml thrombin for 5 minutes as described in panel A.  Human washed platelets were 
fluorescently labelled and incubated with the HUVEC monolayers.  Non-adherent platelets 
were removed by washing and images were collected.  Representative fluorescent images of 
adhered platelets (upper panels) and phase contrast images of the HUVEC monolayers and 
adhered platelets (lower panels) are shown, with quantitation of platelet adhesion from three 
independent experiments (right panel).  Error bars represent the standard error of the mean 
(*P<0.05). 
 
Figure 8.  Tspan18-knockout mice have impaired histamine-induced von Willebrand 
factor release and impaired thombo-inflammatory responses.  (A) Tspan18+/+ and 
Tspan18-/- mice were intraperitoneally-injected with histamine and plasma von Willebrand 
factor (VWF) levels were measured 30 minutes later by ELISA.  Error bars represent 
standard error of the mean from eight Tspan18+/+ and seven Tspan18-/- mice (*P<0.05).  (B) 
Tspan18+/+ and Tspan18-/- mice were anaesthetized, the abdominal aorta exposed and 
mechanically injured through a single firm compression with forceps.  Blood flow was 
subsequently monitored with a Doppler flowmeter to calculate the time until complete 
occlusion of the vessel.  Each symbol represents one animal.  (C) Tspan18+/+ and Tspan18-/- 
mice were anaesthetized and the mesentery was exteriorized through an abdominal incision.  
Platelets were fluorescently labelled with Dylight 488-conjugated anti-GPIX derivative.  
Small mesenteric arterioles were exposed to FeCl3-induced chemical injury via topical 
application.  Time to appearance of the first thrombi was recorded (left panel), and the time 
until complete occlusion of the vessel was measured using fluorescence intravital microscopy 
(right panel).  Each symbol represents one animal.  (D) Tspan18+/+ and Tspan18-/- mice were 
anaesthetized and surgery performed to stenose the inferior vena cava.  After 48 hours, 
thrombus length (left panel) and weight (right panel) were measured.  Each symbol 
represents one animal and horizontal bars represent the median (*P<0.05).  All data in panels 
A-D were analyzed by one-way ANOVA with Dunnett’s multiple comparisons test.  (E) 
Myocardial ischemia-reperfusion injury was induced in the left ventricle of the beating heart 
of anaesthetized mice by occluding the left anterior descending artery for 45 minutes with a 
suture.  Reperfusion was instigated for 2 hours by removal of the ligature, after which the 
organ was harvested.  Frozen sections were analyzed for the presence of platelets in the 
microcirculation by immunofluorescence microscopy.  3 litter-matched pairs of Tspan18+/+ 
and Tspan18-/- mice were used, with 3 sections per mouse and 5 images analyzed per section.  
Each symbol represents one image.  For each image, the integrated density value was 
calculated as a representation of the total number of platelets (left panel), and the average 
aggregate size was also calculated (right panel).  Error bars represent the standard error of the 
mean and data were analyzed by a Mann-Whitney test (****P<0.0001). 
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Supplemental Methods 
 
Cell culture 
The DT40 chicken B-cell line was cultured in RPMI medium (Sigma) containing 10% 
fetal calf serum (Gibco), 1% chicken serum (Sigma), 4 mM L-glutamine, 100 units/ml 
penicillin, 100 µg/ml streptomycin and 50 µM β-mercaptoethanol.  DT40 cells deficient in 
IP3 receptors
1
 were supplied by T. Kurosaki (Osaka University, Japan).  The Jurkat human T-
cell line was cultured in RPMI medium (Sigma) containing 10% bovine calf serum, 4 mM L-
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin.  The human embryonic 
kidney (HEK)-293T (HEK-293 cells expressing the large T-antigen of simian virus 40) cell 
line and the human HeLa epithelial cell line were cultured in DMEM medium (Sigma) 
containing 10% fetal calf serum (Gibco), 4 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin.  Human umbilical vein endothelial cells (HUVECs) were isolated from 
umbilical cords obtained from Birmingham Women’s Health Care NHS Trust with informed 
consent
2
.  HUVECs were cultured in M199 medium (Sigma) containing 10% fetal calf 
serum, 0.2% bovine brain extract, 90 µg/ml heparin and 4 mM L-glutamine, on plates coated 
with 0.1% type 1 gelatin from porcine skin (Sigma). 
 
Quantitative real-time polymerase chain reaction (PCR) 
RNA was extracted using a RNeasy Mini Kit with QIAshredder columns (Qiagen).  
cDNA was generated using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems).  Quantitative real-time PCR was performed using TaqMan assays for Tspan18, 
Orai1, Orai2, Orai3, 18S and GAPDH.  All quantitative PCR data were normalized to 18S or 
GAPDH, as internal loading controls, and relative data was calculated as described
3
. 
 
Lentiviral transduction 
HUVECs were lentivirally transduced with Orai1-Myc using our previously described 
method
4
.  In brief, lentivirus were produced in HEK-293T cells by transfection with the 
psPAX2 lentiviral packaging and pMD2.G envelope constructs, which were gifts from Didier 
Trono (Addgene), and pLVX-EF1α-IRES-Puro (Clontech) into which human Myc-tagged 
Orai1
5
 was subcloned.  Transduced HUVECs were selected in 1 µg/ml puromycin 
(Invitrogen). 
 
NFAT/AP-1-luciferase transcriptional reporter assay 
The NFAT/AP-1-luciferase assay, and β-galactosidase assay to normalize for 
transfection efficiency, were completed as described
6
.  Expression of FLAG-tetraspanin 
constructs was confirmed by SDS-PAGE of cell lysates in 1% Triton X-100, followed by 
western blotting using Western Lightning chemiluminescence reagents (Perkin Elmer) and 
Hyperfilm (Amersham Biosciences). 
 
Co-immunoprecipitation 
Transfected HEK-293T cells were lyzed in 1% digitonin (Merck) followed by co-
immunoprecipitation using anti-FLAG M2-coupled protein G sepharose (Life 
Technologies)
7
.  SDS-PAGE and western blots with anti-Myc and anti-FLAG antibodies, 
followed by specific IRDye fluorescent secondary antibodies, were imaged and quantified on 
the Odyssey Infrared Imaging System (LI-COR Biosciences)
7
. 
 
Immunofluorescence microscopy 
HeLa cells were transfected with FLAG-Tspan18, Orai1-Myc or both expression 
constructs, and stained with CellTracker Deep Red Dye (Invitrogen).  Cells were fixed, 
2 
 
washed and blocked as described
2
, and stained with rabbit anti-Myc and mouse anti-FLAG 
tag antibodies, followed by Alexa488-conjugated anti-rabbit and Alexa568-conjugated anti-
mouse secondary antibodies.  Images were captured on a Zeiss LSM 710 confocal 
microscope using a 40x objective.  The Manders coefficients (M1 and M2) were used as the 
colocalization measure
8
. 
For imaging of HUVECs transfected with Tspan18 siRNA and lentivirally-transduced 
with Myc-tagged Orai1, cells were fixed, washed and blocked as described
2
, and stained with 
rabbit anti-Myc and mouse anti-calnexin antibodies.  Secondary antibodies and confocal 
microscopy was as described above.  To quantify Myc-Orai1 subcellular localization, the 
percentage expression of Orai1 and calnexin across a line spanning the width of each cell was 
determined using ImageJ.  The percentage of Orai1 that localized to a calnexin endoplasmic 
reticulum mask was then quantified. 
For imaging of Weibel-Palade bodies, HUVECs were transfected with Tspan18 
siRNA and 48 hours later were stained with CellTracker Deep Red Dye (Invitrogen).  Cells 
were then stimulated with 1 U/ml thrombin for 5 minutes.  Cells were fixed, washed, blocked 
and stained with anti-VWF antibody, followed by Alexa488-conjugated anti-rabbit secondary 
antibody.  Z-stack images (0.4 μm slices) were analyzed using Fiji.  Images were de-noised 
and the background was subtracted to remove the VWF signal in the ER.  Weibel-Palade 
bodies were then counted from 3D reconstructions. 
For imaging of mouse ear vasculature, anterior ear tissue was prepared and stained as 
previously described
9
, using biotinylated isolectin GS-IB4 glycoprotein and Alexa647-
conjugated streptavidin (ThermoFisher Scientific).  Images of whole mounted ear tissue were 
taken with a Leica DM IRE2 confocal microscope and a 10x objective. 
 
Immunohistochemistry 
 Formalin-fixed paraffin-embedded 5 μm tissue sections were stained and analyzed as 
previously described
10
, using 0.5 μg/ml MECA32 rat anti-mouse panendothelial cell antibody 
or rat IgG2a κ isotype control. 
 
ELISA 
For the HUVEC VWF release studies, complete M199 media was replaced with 
OptiMEM for 16 hours.  Half of the OptiMEM was taken for a baseline reading, and the 
remaining OptiMEM was treated with thrombin (1 U/ml) or histamine (20 µM) for 5 minutes 
before the supernatant was removed.  The media was assayed for VWF release using the 
human VWF ELISA Kit (RayBio). 
 
Platelet aggregation and adhesion to HUVECs 
Mouse washed platelets were isolated from whole blood for lumi-aggregometry
11
.  
For platelet-HUVEC adhesion assays, human washed platelets were labelled with 5 µg/ml 
calcein-AM (Cambridge, Bioscience) and assays performed as described
12
; HUVECs were 
first transfected with Tspan18 siRNA and 48 hours later were stimulated with 1 U/ml 
thrombin for 5 minutes.  Five random fields of the endothelial monolayer were imaged using 
phase-contrast and fluorescence microscopy, and adherent platelets counted using ImageJ. 
 
Coagulation assays 
Mouse plasma samples were used in a prothrombin time test with human placental 
thromboplastin (Thromborel S, Siemens Healthcare Diagnostics Products) and in an activated 
partial thromboplastin time test with purified soy phosphatides with ellagic acid (Actin FS, 
Siemens Healthcare Diagnostics Products).  All tests were performed on a Sysmex CS-5100 
(Sysmex Corporation). 
3 
 
In vivo assays 
Mouse models used litter-matched 8-10 week-old mice.  For measurement of VWF 
release, mice were intra-peritoneally injected with 200 µl 1 mM histamine per 15 g body 
weight.  Blood samples were taken 2 days prior and 30 minutes after injection.  Plasma was 
assayed using the mouse VWF ELISA Kit (Generon).  Arterial thrombosis models 
(mechanical-induced injury of the abdominal aorta and FeCl3-induced injury of mesenteric 
arterioles)
13
 and the inferior vena cava deep vein thrombosis model
14
 were completed as 
described.  For the tail bleeding hemostasis assay, 3 mm of the tail tip was removed and 
blood loss monitored for 20 minutes, or until a maximum blood loss of 15% as estimated by 
weight (assuming a total blood volume of 70 ml/kg)
11
.  Myocardial ischemia-reperfusion 
injury was induced in the left ventricle of the beating heart using a well-established model 
that involved occluding the left anterior descending artery for 45 minutes using a silk 
suture
15
.  Reperfusion was instigated for 2 hours by removal of the ligature, after which the 
organ was harvested.  Isolated hearts were covered in optimum cutting temperature 
compound (Tissue-Tek), before being snap frozen in liquid nitrogen.  Frozen sections of 10 
μm were cut and fixed in acetone for 10 minutes.  For immunofluorescence staining, sections 
were rehydrated in phosphate-buffered saline for 10 minutes, followed by incubation with 10 
μg/ml anti-CD16/32 antibody to block Fc receptors.  Sections were incubated with 10 μg/ml 
allophycocyanin-conjugated anti-CD41 antibody to stain platelets, and viewed using an 
EVOS microscope (ThermoFisher Scientific).  Five fields of view were taken for each heart 
section, and three sections were examined for each mouse, and the images were analyzed 
using ImageJ.  Each field of view was changed to 8-bit and a triangle threshold was added 
before quantitation.  The integrated density value was calculated as a representation of the 
total number of platelets, and the average aggregate size was also calculated. 
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